Navigation Links
Parkinson's Treatment Drugs Even Out Over Long Term
Date:3/11/2009

Levels of disability, quality of life similar on levodopa or pramipexole, study finds

WEDNESDAY, March 11 (HealthDay News) -- Two drugs -- levodopa and pramipexole -- used to treat early stage Parkinson's disease each have advantages and disadvantages, but their overall impact appears to even out over a long period of treatment.

That's the conclusion of a new study that included hundreds of patients in Canada and the United States.

"Clinicians and patients often struggle with what is the right initial approach to treating Parkinson's disease. This study tells us that, over the long haul, patients on the different drugs end up at roughly the same place in terms of their level of disability and quality of life," lead author Dr. Kevin Biglan, a neurologist at the University of Rochester Medical Center in New York, said in a school news release.

The two drugs use different mechanisms to counteract the decline in the production of dopamine in the brain that causes Parkinson's symptoms. Levodopa is an amino acid that the body metabolizes into dopamine. Pramipexole binds with dopamine receptors on cells in the brain and mimics dopamine's molecular function.

Levodopa is considered better at treating motor control problems in Parkinson's patients but is also associated with side effects such as dyskinesia (involuntary movements), and the effectiveness of the drug can wear off over time. Pramipexole is less commonly associated with dyskinesea and wearing off, but is less effective in treating motor control problems and more often causes sleepiness, according to background information in the news release.

Doctors often prescribe pramipexole first, because it extends the length of time a patient can benefit from levodopa before its effect wears off.

The initial study included 301 patients at 22 sites who were followed for two years. A subset of 222 of those patients was followed for an additional four years. At the start of the study, half the patients were randomly selected to receive levodopa and half to receive pramipexole. After six years of follow-up, 90 percent of patients were taking levodopa.

Patients initially treated with levodopa were more likely to develop motor control complications such as dyskinesia and wearing off, but these complications didn't have a significant impact on patients' quality of life or disability, the researchers found.

The study, published online March 9 in the journal Archives of Neurology, was funded by Pharmacia Corp. and Boehringer Ingelheim.

More information

We Move has more about Parkinson's disease.



-- Robert Preidt



SOURCE: University of Rochester Medical Center, news release, March 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Parkinson's Treatment Drugs Even Out Over Long Term
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: